Solid Tumor trials recruiting in Tennessee

All Solid Tumor trials nationally

Cities in Tennessee

Recruiting trials in Tennessee

• A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
  NCT07109726 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Tennessee: Nashville
• A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
  NCT06586957 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Tennessee: Nashville
• A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors
  NCT06440005 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Tennessee: Nashville
• A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
  NCT04300556 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Tennessee: Chattanooga, Nashville
• FIH Trial of VERT-002 in Patients With Locally Advanced or Metastatic Solid Tumors With MET Alterations
  NCT06669117 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Tennessee: Nashville
• FOG-001 in Locally Advanced or Metastatic Solid Tumors
  NCT05919264 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Tennessee: Nashville
• Indocyanine Green (ICG) Guided Tumor Resection
  NCT04084067 · Phase: Phase 1 · Ages: No age limits stated · Sex: All (male and female) · Tennessee: Memphis
• Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion
  NCT05245500 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Tennessee: Nashville
• Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
  NCT05786924 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Tennessee: Nashville
• R-5780-01 In Combination With PD-1 Checkpoint Inhibitors (Checkpoint Protein on Immune Cells Called T Cells) in Patients With Solid Tumors
  NCT06398418 · Phase: Phase 1 · Ages: 18 Years to 80 Years · Sex: All (male and female) · Tennessee: Nashville
• SMP-3124LP in Adults With Advanced Solid Tumors
  NCT06526819 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Tennessee: Nashville
• Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors
  NCT06425926 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Tennessee: Nashville
• Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
  NCT04198766 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Tennessee: Nashville
• Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs.
  NCT07165132 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Tennessee: Nashville
• Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors
  NCT04900818 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Tennessee: Nashville
• Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
  NCT05176483 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Tennessee: Nashville